Published in J Am Soc Nephrol on November 15, 2006
Autosomal dominant polycystic kidney disease: the last 3 years. Kidney Int (2009) 3.66
Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis. Proc Natl Acad Sci U S A (2011) 1.69
The cell biology of polycystic kidney disease. J Cell Biol (2010) 1.58
Small-molecule CFTR inhibitors slow cyst growth in polycystic kidney disease. J Am Soc Nephrol (2008) 1.56
Parasympathetic innervation regulates tubulogenesis in the developing salivary gland. Dev Cell (2014) 1.53
Tolvaptan inhibits ERK-dependent cell proliferation, Cl⁻ secretion, and in vitro cyst growth of human ADPKD cells stimulated by vasopressin. Am J Physiol Renal Physiol (2011) 1.40
A tumor necrosis factor-alpha-mediated pathway promoting autosomal dominant polycystic kidney disease. Nat Med (2008) 1.38
Physiology and pathophysiology of the vasopressin-regulated renal water reabsorption. Pflugers Arch (2008) 1.37
Strategies targeting cAMP signaling in the treatment of polycystic kidney disease. J Am Soc Nephrol (2013) 1.33
Potent, metabolically stable benzopyrimido-pyrrolo-oxazine-dione (BPO) CFTR inhibitors for polycystic kidney disease. J Med Chem (2011) 1.25
Periostin induces proliferation of human autosomal dominant polycystic kidney cells through alphaV-integrin receptor. Am J Physiol Renal Physiol (2008) 1.21
Cyclic AMP-mediated cyst expansion. Biochim Biophys Acta (2010) 1.21
Polycystin-2 and phosphodiesterase 4C are components of a ciliary A-kinase anchoring protein complex that is disrupted in cystic kidney diseases. Proc Natl Acad Sci U S A (2011) 1.18
Nanomolar potency pyrimido-pyrrolo-quinoxalinedione CFTR inhibitor reduces cyst size in a polycystic kidney disease model. J Med Chem (2009) 1.17
Characterization of vasopressin-responsive collecting duct adenylyl cyclases in the mouse. Am J Physiol Renal Physiol (2009) 1.08
Treatment strategies and clinical trial design in ADPKD. Adv Chronic Kidney Dis (2010) 1.05
Polycystic kidney disease: pathogenesis and potential therapies. Biochim Biophys Acta (2010) 1.02
Molecular functions of anoctamin 6 (TMEM16F): a chloride channel, cation channel, or phospholipid scramblase? Pflugers Arch (2013) 1.02
Polycystic kidney diseases: from molecular discoveries to targeted therapeutic strategies. Cell Mol Life Sci (2008) 1.01
Epidermal growth factor-mediated proliferation and sodium transport in normal and PKD epithelial cells. Biochim Biophys Acta (2010) 1.00
Thiazolidinone CFTR inhibitors with improved water solubility identified by structure-activity analysis. Bioorg Med Chem (2008) 0.98
Loss of the ciliary kinase Nek8 causes left-right asymmetry defects. J Am Soc Nephrol (2013) 0.97
Adenylyl cyclase VI mediates vasopressin-stimulated ENaC activity. J Am Soc Nephrol (2012) 0.96
Failure to ubiquitinate c-Met leads to hyperactivation of mTOR signaling in a mouse model of autosomal dominant polycystic kidney disease. J Clin Invest (2010) 0.96
Endogenous concentrations of ouabain act as a cofactor to stimulate fluid secretion and cyst growth of in vitro ADPKD models via cAMP and EGFR-Src-MEK pathways. Am J Physiol Renal Physiol (2012) 0.93
Vasopressin antagonists in polycystic kidney disease. Semin Nephrol (2008) 0.93
The Future of Polycystic Kidney Disease Research--As Seen By the 12 Kaplan Awardees. J Am Soc Nephrol (2015) 0.93
c-Met and NF-κB-dependent overexpression of Wnt7a and -7b and Pax2 promotes cystogenesis in polycystic kidney disease. J Am Soc Nephrol (2012) 0.92
Drug discovery for polycystic kidney disease. Acta Pharmacol Sin (2011) 0.90
Food Restriction Ameliorates the Development of Polycystic Kidney Disease. J Am Soc Nephrol (2015) 0.88
Hypoxia-inducible factor-1α causes renal cyst expansion through calcium-activated chloride secretion. J Am Soc Nephrol (2013) 0.87
CFTR and defective endocytosis: new insights in the renal phenotype of cystic fibrosis. Pflugers Arch (2008) 0.86
Novel functional complexity of polycystin-1 by GPS cleavage in vivo: role in polycystic kidney disease. Mol Cell Biol (2014) 0.86
Downregulating hedgehog signaling reduces renal cystogenic potential of mouse models. J Am Soc Nephrol (2014) 0.85
Ex vivo modeling of chemical synergy in prenatal kidney cystogenesis. PLoS One (2013) 0.84
Phosphodiesterase 1A modulates cystogenesis in zebrafish. J Am Soc Nephrol (2014) 0.82
Impaired glomerulogenesis and endothelial cell migration in Pkd1-deficient renal organ cultures. Biochem Biophys Res Commun (2014) 0.82
Kidney: polycystic kidney disease. Wiley Interdiscip Rev Dev Biol (2014) 0.81
Phosphodiesterase Isoform Regulation of Cell Proliferation and Fluid Secretion in Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol (2015) 0.81
Vasopressin-2 receptor signaling and autosomal dominant polycystic kidney disease: from bench to bedside and back again. J Am Soc Nephrol (2014) 0.79
Aquaporin-1 retards renal cyst development in polycystic kidney disease by inhibition of Wnt signaling. FASEB J (2015) 0.79
Ginkgolide B inhibits renal cyst development in in vitro and in vivo cyst models. Am J Physiol Renal Physiol (2012) 0.78
Novel role of ouabain as a cystogenic factor in autosomal dominant polycystic kidney disease. Am J Physiol Renal Physiol (2013) 0.78
Chloride secretion by renal collecting ducts. Curr Opin Nephrol Hypertens (2015) 0.77
Ouabain Regulates CFTR-Mediated Anion Secretion and Na,K-ATPase Transport in ADPKD Cells. J Membr Biol (2015) 0.77
Experimental therapies and ongoing clinical trials to slow down progression of ADPKD. Curr Hypertens Rev (2013) 0.76
Dibutyryl-cAMP attenuates pulmonary fibrosis by blocking myofibroblast differentiation via PKA/CREB/CBP signaling in rats with silicosis. Respir Res (2017) 0.75
New Insights into the Molecular Mechanisms Targeting Tubular Channels/Transporters in PKD Development. Kidney Dis (Basel) (2016) 0.75
Anticystogenic activity of a small molecule PAK4 inhibitor may be a novel treatment for autosomal dominant polycystic kidney disease. Kidney Int (2017) 0.75
RAPAMYCIN INCREASES LENGTH AND MECHANOSENSORY FUNCTION OF PRIMARY CILIA IN RENAL EPITHELIAL AND VASCULAR ENDOTHELIAL CELLS. Int Educ Res J (2016) 0.75
Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med (2012) 9.88
Blood pressure in early autosomal dominant polycystic kidney disease. N Engl J Med (2014) 5.01
Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort. Kidney Int (2003) 4.84
Comprehensive molecular diagnostics in autosomal dominant polycystic kidney disease. J Am Soc Nephrol (2007) 3.26
Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol (2012) 2.78
Increased water intake decreases progression of polycystic kidney disease in the PCK rat. J Am Soc Nephrol (2006) 2.77
Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells. Kidney Int (2004) 2.55
Evaluation of urine biomarkers of kidney injury in polycystic kidney disease. Kidney Int (2012) 2.39
Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort. Clin J Am Soc Nephrol (2005) 2.37
Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant polycystic kidneys. Kidney Int (2003) 2.32
Calcium restriction allows cAMP activation of the B-Raf/ERK pathway, switching cells to a cAMP-dependent growth-stimulated phenotype. J Biol Chem (2004) 2.26
Cyst number but not the rate of cystic growth is associated with the mutated gene in autosomal dominant polycystic kidney disease. J Am Soc Nephrol (2006) 2.21
Calcium restores a normal proliferation phenotype in human polycystic kidney disease epithelial cells. J Am Soc Nephrol (2005) 1.87
Gastrointestinal outcomes and confounders in cystic fibrosis. J Pediatr Gastroenterol Nutr (2005) 1.87
Human podocytes adhere to the KRGDS motif of the alpha3alpha4alpha5 collagen IV network. J Am Soc Nephrol (2008) 1.81
KCa3.1 potassium channels are critical for cAMP-dependent chloride secretion and cyst growth in autosomal-dominant polycystic kidney disease. Kidney Int (2008) 1.80
Cilia-like structures and polycystin-1 in osteoblasts/osteocytes and associated abnormalities in skeletogenesis and Runx2 expression. J Biol Chem (2006) 1.68
Angiotensin blockade in late autosomal dominant polycystic kidney disease. N Engl J Med (2014) 1.64
Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience. Clin J Am Soc Nephrol (2011) 1.63
Imaging for the prognosis of autosomal dominant polycystic kidney disease. Nat Rev Nephrol (2010) 1.63
Partial rescue of glomerular laminin alpha5 mutations by wild-type endothelia produce hybrid glomeruli. J Am Soc Nephrol (2007) 1.62
Cellular origins of type IV collagen networks in developing glomeruli. J Am Soc Nephrol (2009) 1.59
Characterization of large rearrangements in autosomal dominant polycystic kidney disease and the PKD1/TSC2 contiguous gene syndrome. Kidney Int (2008) 1.58
Sorafenib inhibits cAMP-dependent ERK activation, cell proliferation, and in vitro cyst growth of human ADPKD cyst epithelial cells. Am J Physiol Renal Physiol (2010) 1.58
Polycystin-1 activation of c-Jun N-terminal kinase and AP-1 is mediated by heterotrimeric G proteins. J Biol Chem (2002) 1.58
The medicinal use of water in renal disease. Kidney Int (2013) 1.56
Bacterial overgrowth in the cystic fibrosis transmembrane conductance regulator null mouse small intestine. Infect Immun (2004) 1.53
Magnetic resonance measurements of renal blood flow and disease progression in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol (2006) 1.53
Macrophage migration inhibitory factor promotes cyst growth in polycystic kidney disease. J Clin Invest (2015) 1.51
Novel approach to estimate kidney and cyst volumes using mid-slice magnetic resonance images in polycystic kidney disease. Am J Nephrol (2013) 1.50
Sonographic assessment of the severity and progression of autosomal dominant polycystic kidney disease: the Consortium of Renal Imaging Studies in Polycystic Kidney Disease (CRISP). Am J Kidney Dis (2005) 1.49
Acetylation of beta-catenin by CREB-binding protein (CBP). J Biol Chem (2002) 1.47
Urinary excretion of monocyte chemoattractant protein-1 in autosomal dominant polycystic kidney disease. J Am Soc Nephrol (2003) 1.46
Magnetic resonance measurements of renal blood flow as a marker of disease severity in autosomal-dominant polycystic kidney disease. Kidney Int (2003) 1.45
Renal activation of extracellular signal-regulated kinase in rats with autosomal-dominant polycystic kidney disease. Kidney Int (2003) 1.42
Tolvaptan inhibits ERK-dependent cell proliferation, Cl⁻ secretion, and in vitro cyst growth of human ADPKD cells stimulated by vasopressin. Am J Physiol Renal Physiol (2011) 1.40
Inflammation of the cystic fibrosis mouse small intestine. Am J Physiol Gastrointest Liver Physiol (2004) 1.40
Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study. Am J Kidney Dis (2011) 1.39
A tumor necrosis factor-alpha-mediated pathway promoting autosomal dominant polycystic kidney disease. Nat Med (2008) 1.38
Comparison of methods for determining renal function decline in early autosomal dominant polycystic kidney disease: the consortium of radiologic imaging studies of polycystic kidney disease cohort. J Am Soc Nephrol (2006) 1.37
Loss of alpha3/alpha4(IV) collagen from the glomerular basement membrane induces a strain-dependent isoform switch to alpha5alpha6(IV) collagen associated with longer renal survival in Col4a3-/- Alport mice. J Am Soc Nephrol (2006) 1.35
A case for water in the treatment of polycystic kidney disease. Clin J Am Soc Nephrol (2009) 1.31
A mutant receptor tyrosine phosphatase, CD148, causes defects in vascular development. Mol Cell Biol (2003) 1.27
Polycystin-1 activates the calcineurin/NFAT (nuclear factor of activated T-cells) signaling pathway. J Biol Chem (2004) 1.26
MRI-based kidney volume measurements in ADPKD: reliability and effect of gadolinium enhancement. Clin J Am Soc Nephrol (2009) 1.24
Secretion of cytokines and growth factors into autosomal dominant polycystic kidney disease liver cyst fluid. Hepatology (2004) 1.21
Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol (2010) 1.21
Transmembrane domain analysis of polycystin-1, the product of the polycystic kidney disease-1 (PKD1) gene: evidence for 11 membrane-spanning domains. Biochemistry (2003) 1.17
Ouabain binds with high affinity to the Na,K-ATPase in human polycystic kidney cells and induces extracellular signal-regulated kinase activation and cell proliferation. J Am Soc Nephrol (2006) 1.15
Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases. Clin J Am Soc Nephrol (2010) 1.12
Urinary proteomic biomarkers for diagnosis and risk stratification of autosomal dominant polycystic kidney disease: a multicentric study. PLoS One (2013) 1.12
Autocrine extracellular purinergic signaling in epithelial cells derived from polycystic kidneys. Am J Physiol Renal Physiol (2002) 1.12
Polycystin-dependent fluid flow sensing targets histone deacetylase 5 to prevent the development of renal cysts. Development (2010) 1.10
Laminin compensation in collagen alpha3(IV) knockout (Alport) glomeruli contributes to permeability defects. J Am Soc Nephrol (2007) 1.10
Mouse stem cells seeded into decellularized rat kidney scaffolds endothelialize and remodel basement membranes. Organogenesis (2012) 1.09
Stem cell therapy for Alport syndrome: the hope beyond the hype. Nephrol Dial Transplant (2008) 1.07
Electrolyte and fluid secretion by cultured human inner medullary collecting duct cells. Am J Physiol Renal Physiol (2002) 1.07
Water prescription in autosomal dominant polycystic kidney disease: a pilot study. Clin J Am Soc Nephrol (2010) 1.06
PPAR-gamma agonist ameliorates kidney and liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease. Am J Physiol Renal Physiol (2010) 1.05
Acute podocyte vascular endothelial growth factor (VEGF-A) knockdown disrupts alphaVbeta3 integrin signaling in the glomerulus. PLoS One (2012) 1.05
The effect of caffeine on renal epithelial cells from patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol (2002) 1.01
Cystic fibrosis transmembrane conductance regulator knockout mice exhibit aberrant gastrointestinal microbiota. Gut Microbes (2012) 1.01
Podocyte expression of hypoxia-inducible factor (HIF)-1 and HIF-2 during glomerular development. J Am Soc Nephrol (2003) 1.01
Macrophages promote polycystic kidney disease progression. Kidney Int (2013) 1.01
Aberrant polycystin-1 expression results in modification of activator protein-1 activity, whereas Wnt signaling remains unaffected. J Biol Chem (2004) 1.00
Integration of embryonic stem cells in metanephric kidney organ culture. J Am Soc Nephrol (2005) 1.00
Inhibition of histone deacetylases targets the transcription regulator Id2 to attenuate cystic epithelial cell proliferation. Kidney Int (2011) 1.00
Return of the secretory kidney. Am J Physiol Renal Physiol (2002) 0.98
Detected renal cysts are tips of the iceberg in adults with ADPKD. Clin J Am Soc Nephrol (2012) 0.97
The polycystic kidney disease-1 promoter is a target of the beta-catenin/T-cell factor pathway. J Biol Chem (2002) 0.95
Polycystic kidney disease in Han:SPRD Cy rats is associated with elevated expression and mislocalization of SamCystin. Am J Physiol Renal Physiol (2010) 0.95
Oxidant stress and reduced antioxidant enzyme protection in polycystic kidney disease. J Am Soc Nephrol (2002) 0.94
Endogenous concentrations of ouabain act as a cofactor to stimulate fluid secretion and cyst growth of in vitro ADPKD models via cAMP and EGFR-Src-MEK pathways. Am J Physiol Renal Physiol (2012) 0.93
Identification of a forskolin-like molecule in human renal cysts. J Am Soc Nephrol (2007) 0.93
Decay-accelerating factor expression in the rat kidney is restricted to the apical surface of podocytes. Kidney Int (2002) 0.92
A mouse model of acrodermatitis enteropathica: loss of intestine zinc transporter ZIP4 (Slc39a4) disrupts the stem cell niche and intestine integrity. PLoS Genet (2012) 0.92
Smac-mimetic-induced epithelial cell death reduces the growth of renal cysts. J Am Soc Nephrol (2013) 0.92